SE0301906D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0301906D0
SE0301906D0 SE0301906A SE0301906A SE0301906D0 SE 0301906 D0 SE0301906 D0 SE 0301906D0 SE 0301906 A SE0301906 A SE 0301906A SE 0301906 A SE0301906 A SE 0301906A SE 0301906 D0 SE0301906 D0 SE 0301906D0
Authority
SE
Sweden
Prior art keywords
hydrogen
new compounds
nhar
nitro
halogen
Prior art date
Application number
SE0301906A
Other languages
Swedish (sv)
Inventor
Rhonan Ford
Frederic Leroux
Michael Stocks
Britt-Marie Swahn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0301906A priority Critical patent/SE0301906D0/en
Publication of SE0301906D0 publication Critical patent/SE0301906D0/en
Priority to PCT/SE2004/001015 priority patent/WO2004113303A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

The present invention relates to new compounds of formula (I) in which:X is CR<4> or N; R<1> is -OR<5>, -NHCOR<6> or -NR<6>R<7>; R<2 >is hydrogen, Oar<1> or -NHAr<1> wherein Ar<1> is aryl optionally substituted with one or more of R<8>, -OR<8>, -NR<8>R<9>, -CONR<8>R<9>, -COOR<8>, -NR<8>COR<9>, -SR<8>, -SO2NR<8>R<9>, -NR<8>SO2 R<9>, halogen, cyano, or nitro; R<3> is hydrogen or -NHAr<2> wherein Ar<2> is benzene optionally substituted with one or more of R<8>, -OR<8>, -NR<8>R<9>, halogen or nitro, wherein R<2> and R<3> is not simultaneously hydrogen; a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.
SE0301906A 2003-06-26 2003-06-26 New compounds SE0301906D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE0301906A SE0301906D0 (en) 2003-06-26 2003-06-26 New compounds
PCT/SE2004/001015 WO2004113303A1 (en) 2003-06-26 2004-06-23 INDAZOLE/PYRZOLO[4,3-c]PYRIDIN DERIVATIVES AS JNK INHIBITORS, COMPOSITIONS AND METHODS RELATED THERETO AS WELL AS INTERMEDIATE THEREOF

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301906A SE0301906D0 (en) 2003-06-26 2003-06-26 New compounds

Publications (1)

Publication Number Publication Date
SE0301906D0 true SE0301906D0 (en) 2003-06-26

Family

ID=27656639

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301906A SE0301906D0 (en) 2003-06-26 2003-06-26 New compounds

Country Status (2)

Country Link
SE (1) SE0301906D0 (en)
WO (1) WO2004113303A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4617299B2 (en) * 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド p38 inhibitors and methods of use thereof
DE102004028862A1 (en) * 2004-06-15 2005-12-29 Merck Patent Gmbh 3-aminoindazoles
EP1926734A1 (en) * 2005-08-22 2008-06-04 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
MX2008002385A (en) 2005-08-25 2008-03-18 Hoffmann La Roche P38 map kinase inhibitors and methods for using the same.
JP5131990B2 (en) 2006-01-31 2013-01-30 アレイ バイオファーマ、インコーポレイテッド Kinase inhibitors and methods of use thereof
JP2010513370A (en) 2006-12-19 2010-04-30 エフ．ホフマン−ラ ロシュ アーゲー Pyrazolo [3,4-d] pyrimidine p38 MAP kinase inhibitor
AR071780A1 (en) 2008-05-15 2010-07-14 Nerviano Medical Sciences Srl BICYCLE CARBONILAMINO-PIRAZOLES CARBAMILILE DERIVATIVES AS PROFARMACOS
EP2789615B1 (en) 2009-08-11 2017-05-03 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
BR112012023021A2 (en) * 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc indazole compounds and their uses
EP2822935B1 (en) 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP2689778A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
EP2689779A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
AU2013343105B2 (en) 2012-11-08 2016-04-14 Pfizer Inc. Heteroaromatic compounds as dopamine D1 ligands
EP3043784B9 (en) 2013-09-09 2019-11-20 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
US20160264551A1 (en) 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2016096709A1 (en) 2014-12-16 2016-06-23 Eudendron S.R.L. Heterocyclic derivatives modulating activity of certain protein kinases
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
WO2016145032A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US10155726B2 (en) 2015-03-11 2018-12-18 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
MX2018008815A (en) 2016-01-21 2019-03-28 Zibo Biopolar Changsheng Pharmaceutical Co Ltd Bruton's tyrosine kinase inhibitors.
US10793566B2 (en) 2016-01-21 2020-10-06 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
CN115746000A (en) 2016-03-11 2023-03-07 嘉兴和剂药业有限公司 Compounds and methods for modulating bruton's tyrosine kinase
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
EP4046688A4 (en) * 2019-10-18 2023-09-27 Takeda Pharmaceutical Company Limited Heterocyclic compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL340412A1 (en) * 1997-10-20 2001-01-29 Hoffmann La Roche Bicyclic kinase inhibitors
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020506A1 (en) * 2000-08-22 2002-07-09 Glaxo Group Ltd PIRAZOLE DERIVATIVES FUSED AS PROTEIN KINASE INHIBITORS
DE60234510D1 (en) * 2001-04-16 2010-01-07 Eisai R&D Man Co Ltd 1H-INDAZONE COMPOUNDS THE JNK HEMMEN
TW200302722A (en) * 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
WO2004113303A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
SE0301906D0 (en) New compounds
ES2145922T3 (en) USEFUL SPYRO-AZABICYCLIC COMPOUNDS IN THERAPY.
BR0113234A (en) Polymorphs of an epothilone analog
SE0200979D0 (en) New compounds
ATE113284T1 (en) PURINE COMPOUNDS, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS.
ES2122076T3 (en) DERIVATIVES OF NOR-BILIAR ACIDS, PROCEDURE FOR THE PREPARATION AND USE OF THESE COMPOUNDS AS MEDICINES.
ECSP088404A (en) NEW IMIDAZO DERIVATIVES [4,5-B] PIRIDINE AS INHIBITORS OF THE GLUCÓGENO SINTASA QUINASA 3, FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS
HUP0101999A2 (en) 4-hydroxyquinoline-3-carboxamides and hydrazides use of them and pharmaceutical compositions containing them
ECSP034916A (en) SUBSTITUTED OXAZOLIDINONES FOR COMBINATION THERAPY
NO802352L (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE IMIDAZOLD DERIVATIVES.
EA200400664A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING METHFORMIN AND GLIBENCLAMIDE, APPLIED TO THE TREATMENT OF TYPE II DIABETES
SE0100569D0 (en) New compounds
ES2147320T3 (en) DERIVATIVES OF N- (3-BENZOFURANIL) UREA.
UY29823A1 (en) SUBSTITUTED DERIVATIVES OF 7-CHLORINE-3H-IMIDAZOL- (4,5-B) PIRIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESSES FOR THE PREPARATION OF THE SAME AND APPLICATIONS
TR200200263T2 (en) New selective retinoid agonists
SE0102055D0 (en) New Compounds
BR0315958A (en) Compound, pharmaceutical composition, process for preparing a compound, new intermediates and use of the compound
BRPI0417714A (en) compound, pharmaceutical composition, and use of a compound
AR001769A1 (en) Benzamide enterokinetics pharmaceutical compositions containing them, a process for the preparation of said pharmaceutical compositions, the use of said compounds for the manufacture of medicines and a process for their preparation.
SE0101322D0 (en) Novel compounds
PT870761E (en) TIOCOLCHYCIN DERIVATIVES WITH ANTI-INFLAMMATORY AND MUSCULAR RELAXANT ACTIVITIES
PE20050393A1 (en) BENZOPYRANE COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF INFLAMMATION-RELATED CONDITIONS
IT1255704B (en) HETEROCYCLIC AMINES USEFUL IN THERAPY OF ASTHMA AND AIRWAY INFLAMMATION
HRP20050831A2 (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
BR9611276A (en) Compound pharmaceutical formulation process for treatment or prophylaxis of diseases or conditions of humans and use of a compound